---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-025417"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:37:00.815596+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q2 revenue $11.4M, net loss $3.8M; raises FY2025 revenue guidance to $50-52M

## Summary
- Q2 total revenue $11.4M vs $12.1M YoY; Advanced Energy flat at $9.7M, OEM down 28.5% to $1.7M.
- Net loss attributable to stockholders $3.8M ($0.09/shr) vs $6.6M ($0.19/shr) YoY; adjusted EBITDA loss $2.0M vs $4.3M.
- Soft launch of AYON Body Contouring System exceeding expectations; commercial launch planned September 2025.
- Renuvion launched in China via partner GlamMoon; initial procedures completed with strong clinical interest.
- FY2025 revenue guidance raised to $50-52M (from $47.6-49M); Advanced Energy guidance $42-44M.

## SEC filing metadata
- accession: 0001437749-25-025417
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774925025417/0001437749-25-025417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774925025417/apyx20250526_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-025417
- JSON: https://secwatch.observer/filing/0001437749-25-025417.json
- Plain text: https://secwatch.observer/filing/0001437749-25-025417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.